How Common Is Sjögren’s Syndrome?

Sjögren’s syndrome affects somewhere between roughly 1 in 1,300 and 1 in 200 people, depending on which study you look at and which diagnostic criteria were applied. A 2014 meta-analysis estimated about 61 cases per 100,000 people overall, dropping to about 43 per 100,000 in studies that drew from the general population rather than clinical referrals.¹ That spread is wide enough to matter, and the reason it exists tells you something important about the disease itself: Sjögren’s is genuinely hard to pin down, which means it is almost certainly more common than the diagnosed numbers suggest.

What the Prevalence Numbers Actually Show

A 2024 systematic review pulling together 62 studies found that prevalence estimates for primary Sjögren’s ranged from 0.03% to 0.77% of the population, with incidence rates spanning from about 3.5 to 26 new cases per 100,000 people per year.² In Germany, the estimated prevalence is at least 0.4%, which would make Sjögren’s one of the more common inflammatory rheumatic diseases.³ That’s not a rare disease by most definitions, though it’s far less well-known than conditions like rheumatoid arthritis or lupus that affect similar or even smaller populations.

The enormous range in reported prevalence isn’t just noise. It reflects real differences in how researchers define and detect the condition. The diagnostic criteria for Sjögren’s have changed several times over the decades, and studies using older criteria tend to produce different numbers than those using newer ones. Study design matters too: surveys that start with the general population and test everyone find different rates than studies that look at who shows up at rheumatology clinics.⁴ This isn’t just an academic problem. It means global and temporal trends are genuinely difficult to track, and it makes planning healthcare resources for Sjögren’s patients harder than it should be.

Primary Versus Secondary Forms

When people talk about “how common” Sjögren’s is, they usually mean the primary form, where dryness of the eyes and mouth and immune system dysfunction appear on their own. But Sjögren’s also shows up alongside other autoimmune diseases, particularly rheumatoid arthritis, lupus, and scleroderma. This secondary form is common enough to substantially inflate the total count. A population-based study in Madrid classified about 65% of Sjögren’s patients as having the primary form and about 35% as secondary.⁵

Among people with rheumatoid arthritis specifically, Sjögren’s is strikingly common. Data from a large US registry found that roughly 30% of RA patients had co-occurring Sjögren’s, and that rate climbed with disease duration, reaching nearly 39% in people who had lived with RA for over a decade.⁶ If you have one autoimmune disease, the odds of developing Sjögren’s symptoms on top of it are considerably higher than the population-wide prevalence would suggest.

The Nine-to-One Sex Ratio

Sjögren’s syndrome has one of the most lopsided sex ratios in medicine. Women outnumber men by about nine to one, and the typical onset falls in the forties or fifties, often around or after menopause.⁷ That timing is not a coincidence. Estrogen appears to protect the glands that produce tears and saliva by shielding their secretory cells from a kind of programmed cell death called apoptosis. When estrogen levels fall during menopause, those cells become more vulnerable. Men, meanwhile, produce testosterone that gets converted in the exocrine glands into a compound that serves a similar protective role.

The hormonal story goes deeper. Estrogen stimulates B cells, boosting antibody production, including autoantibodies that attack the body’s own tissue. Androgens do the opposite, suppressing B cell activity.⁸ A case-control study also found that women with primary Sjögren’s had lower cumulative estrogen exposure across their lifetimes compared to controls with dry-eye symptoms alone, suggesting that estrogen’s protective effects on the glands may matter more than its immune-stimulating effects in determining who gets the disease.⁹

When Men Do Get It

The nine-to-one ratio means men are a small minority of Sjögren’s patients, but they are not absent. And their experience with the disease tends to look different. One Swedish population-based study found that men presented with more extraglandular manifestations at diagnosis, meaning the disease was affecting organs beyond the eyes and mouth, and that men had higher levels of a specific autoantibody (anti-Ro52) than women who were also antibody-positive.¹⁰

However, the picture is not entirely consistent across studies. A study from an international registry reported that male patients actually complained less about dryness and showed fewer glandular dysfunctions, yet had higher rates of pulmonary involvement and lymphoma.¹¹ A Chinese study similarly found that men had more extraglandular complications and distinct immune cell profiles.¹² The broad takeaway across these studies is that men with Sjögren’s often have a somewhat different disease phenotype, sometimes milder in the glands but potentially more serious elsewhere. This can also make it harder to recognize in men, since clinicians may be expecting a classic dryness presentation.

Sjögren’s in Children

Sjögren’s is increasingly recognized in pediatric patients, though it remains uncommon in children and often looks different from the adult form. Kids tend to present with swollen parotid glands rather than the classic dry eyes and dry mouth that raise red flags in adults.¹³ A study of 54 children with Sjögren’s found that only about 13% reported dry mouth and 9% reported dry eyes, far lower rates than in adults. Antibody tests, on the other hand, were frequently positive: anti-Ro/SSA antibodies were found in over 94% of the pediatric cases. The average age at symptom onset was about 10 years, and girls outnumbered boys roughly 10 to 1.¹⁴ Because the hallmark dryness symptoms are often absent in children, the disease can go unrecognized for years.

Diagnostic Delays and the Undercount Problem

One reason the true prevalence of Sjögren’s is likely higher than published figures is that diagnosis takes a long time. A Taiwanese population-based study found a median delay of nearly two years between the first appearance of dryness symptoms and an initial Sjögren’s diagnosis, with women waiting slightly longer than men (about 118 weeks versus 94 weeks).¹⁵ A smaller cross-sectional study in Saudi Arabia reported a mean delay of about two years as well, with some patients waiting as long as 11 years.¹⁶

Several factors drive this. Dry eyes and dry mouth are common complaints with many causes, from aging to medications to simple dehydration. Most people who experience them never develop Sjögren’s. Primary-care physicians may not think of an autoimmune condition when confronted with these everyday symptoms. The confirmatory tests, including specific blood antibodies and sometimes a lip biopsy, are not part of routine screening. All of this means there is a substantial population of undiagnosed Sjögren’s patients who don’t appear in any prevalence estimate.

Race, Ethnicity, and Geography

Sjögren’s does not affect all populations equally, though the data are less robust than for some other autoimmune diseases. A study in New York County found that incidence was highest among non-Latina Asian women and non-Latina White women, and significantly lower among Latina and non-Latina Black women.¹⁷ Interestingly, a separate analysis found that American Indian patients with Sjögren’s, while having lower rates of some classic antibodies, actually had higher disease activity scores than White and Black patients, with more joint and gland involvement.¹⁸

Geography also appears to shape how the disease presents. A large international analysis reported a consistent north-south gradient across Europe, the Americas, and Asia: patients diagnosed in southern regions had significantly higher disease activity scores at baseline than those in northern regions.¹⁹ Whether this reflects differences in environmental triggers, genetics, healthcare access patterns, or how far the disease progresses before diagnosis remains unclear. But it means that living in different parts of the world can shape not just whether you get Sjögren’s, but how severe it is when it shows up.

Genetics and Family Risk

Having a first-degree relative with Sjögren’s syndrome increases your own risk substantially. A large nationwide study found an adjusted relative risk of about 12 for people with an affected parent, sibling, or child.²⁰ Siblings had about 19 times the risk, and cotwins of affected patients had an extraordinarily elevated risk. But perhaps more interesting for anyone with Sjögren’s in the family is that the genetic risk doesn’t stay confined to that one disease. First-degree relatives of Sjögren’s patients had about six times the risk of developing lupus, about three times the risk of rheumatoid arthritis, and roughly double the risk of type 1 diabetes and multiple sclerosis. Autoimmune diseases cluster in families, and Sjögren’s sits squarely in the middle of that cluster.

Antibodies Without Symptoms

An intriguing wrinkle in the prevalence question is that some people carry the signature antibodies of Sjögren’s, particularly anti-SSA/Ro, without ever developing clinical disease. A Chinese health-screening study of over 64,000 people found that about 1.7% were positive for anti-SSA antibodies, with the rate higher in women (2.7%) than men (0.9%).²¹ Japanese screening data also found anti-SSA/Ro antibodies at surprisingly high rates in healthy individuals.²² Similar findings have turned up in Ghanaian populations as well.²³

This doesn’t mean those people all have undiagnosed Sjögren’s. Carrying an autoantibody is not the same as having a disease. But it does suggest that the immune system changes underlying Sjögren’s exist on a spectrum, and that the threshold between “positive antibody, no symptoms” and “full clinical disease” may be crossed when additional triggers line up, whether hormonal, environmental, or infectious.

The Role of Viral Triggers

Among those potential triggers, viral infections get the most attention. Epstein-Barr virus, the pathogen behind mononucleosis, has the strongest association with Sjögren’s onset. The working theory is that certain viruses infect the salivary or lacrimal glands and provoke an immune reaction that, in genetically susceptible people, doesn’t shut off properly. The virus essentially kick-starts a process where the immune system begins recognizing the body’s own gland tissue as foreign.²⁴ This helps explain why Sjögren’s doesn’t follow simple inheritance patterns: you can have the genetic susceptibility and the antibodies and still never develop the disease unless the right (or rather, wrong) environmental trigger comes along.

Comorbidities Beyond the Glands

Sjögren’s is often thought of as a “dryness disease,” but it reaches well beyond the eyes and mouth. A registry of over 900 Spanish patients found that the most common extraglandular manifestations involved the joints, the lungs, and the peripheral nervous system, with up to 56% of patients showing activity in at least one organ system beyond the glands during follow-up.²⁵

Autoimmune thyroid disease deserves a special mention. Primary Sjögren’s was found to be about ten times more frequent in people with autoimmune thyroid disease than in the general population, and the reverse was also true: autoimmune thyroiditis was about nine times more common in Sjögren’s patients.²⁶ If you have one, screening for the other makes clinical sense.

The Lymphoma Connection

One of the more serious long-term risks for people with Sjögren’s is lymphoma, particularly non-Hodgkin’s lymphoma. The risk has been estimated at somewhere between 4 and 19 times higher than in the general population, the highest lymphoma risk of any autoimmune disease.²⁷ A Taiwanese population-based cohort study estimated the adjusted hazard ratio at about 4.3.²⁸ The most common type is MALT lymphoma, a slow-growing cancer that arises in mucous membrane tissue, followed by other B-cell lymphomas.²⁹

In absolute terms, the risk is still relatively low: most Sjögren’s patients will never develop lymphoma. But the elevated relative risk is why rheumatologists monitor patients for warning signs like persistent swelling of the parotid glands, unexplained weight loss, and falling levels of certain complement proteins in the blood.

Survival and Long-Term Outlook

The news on overall mortality is mostly reassuring. A meta-analysis of cohort studies found a pooled standardized mortality ratio of 1.38 for primary Sjögren’s compared to the general population, but the confidence interval crossed 1.0, meaning the study could not confirm a statistically significant increase in all-cause mortality.³⁰ A Korean nationwide study found 5-year survival of about 97%, with a standardized mortality ratio of about 1.5, somewhat higher in men than in women.³¹ A large multicentre cohort followed for an average of nearly nine years recorded a cumulative risk of death of about 5% at five years and about 10% at ten years.³²

The upshot is that Sjögren’s is a chronic disease you live with for decades, not one that dramatically shortens life for most patients. Where the risk concentrates is in the subgroup who develop serious complications, particularly lymphoma, severe lung disease, or kidney involvement.

The Economic Weight of a “Minor” Disease

Sjögren’s often gets characterized as a quality-of-life disease rather than a life-threatening one, which can make it feel minor. The economic data tell a different story. In France, median annual healthcare costs for primary Sjögren’s patients ranged from about €2,300 to €4,300, and mean costs reached as high as €9,700 per patient per year, driven up by the patients with the most severe disease. For those with Sjögren’s plus another autoimmune condition, costs climbed further, with mean annual spending exceeding €13,000.³³ US data similarly show that Sjögren’s patients use about 1.6 times the healthcare resources of matched comparators, and those with extraglandular disease use nearly three times as much as those with glandular disease only.³⁴ For a disease with no approved cure and limited targeted treatments, those costs come largely from managing symptoms and monitoring for complications rather than from a single expensive therapy.